Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that came in ahead of analyst expectations, with the gene-editing company posting a smaller-than-expected loss and stronger revenue. The company reported a loss of $0.06 per share, beating the consensus estimate for a $0.23 loss.
Revenue totaled $24.74 million, well above the analyst forecast of $8.02 million, although it declined from $30.6 million recorded in the same quarter last year.
Following the announcement, shares of the company rose about 2% in pre-market trading.
Collaboration and other research and development revenue fell 19% year over year, mainly due to milestone payments recognized under the company’s partnership with Bristol Myers Squibb in the fourth quarter of 2024.
“We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, President and Chief Executive Officer of Editas Medicine.
Editas reported a net loss of $5.6 million for the quarter, significantly narrower than the $45.4 million loss recorded in the same period a year earlier.
Research and development expenses dropped by $21.2 million to $27.4 million, largely reflecting lower clinical trial and manufacturing costs after the company discontinued its reni-cel program in December 2024.
General and administrative expenses also declined, falling $5.0 million to $11.4 million.
At the end of the quarter, Editas held $146.6 million in cash and cash equivalents, compared with $269.9 million a year earlier. The company said its current cash reserves are expected to fund operations through the third quarter of 2027.
Editas also confirmed it remains on track to submit an IND/CTA application for its lead candidate EDIT-401 by mid-2026 and plans to launch a first-in-human clinical trial later this year in patients with heterozygous familial hypercholesterolemia.
In preclinical studies, EDIT-401 achieved an average reduction of more than 90% in LDL cholesterol levels. The company expects to generate initial proof-of-concept data in humans by the end of 2026.